Log In
Print
BCIQ
Print
Print this Print this
 

Janumet, sitagliptin/metformin (MK-0431A) (ONO-5435A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of Januvia sitagliptin phosphate plus metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; AMP-activated protein kinase (AMPK)
Mechanism of ActionAMP-activated protein kinase (AMPK) activator; Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Ono Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today